Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker DXCM · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Aug 11, 2026 | Stelo Glucose Biosensor System | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K262472 ↗ |
| Jun 12, 2026 | Stelo Glucose Biosensor System | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K260935 ↗ |
| Jun 8, 2026 | Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15… | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K261402 ↗ |
| May 21, 2026 | Stelo Glucose Biosensor System | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K261359 ↗ |
| Feb 3, 2026 | Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexco… | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K253737 ↗ |
| Dec 17, 2025 | Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexco… | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K253710 ↗ |
| Nov 18, 2025 | Dexcom Smart Basal | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K252818 ↗ |
| Apr 9, 2025 | Dexcom G7 15 Day Continuous Glucose Monitoring System | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K243214 ↗ |
| Apr 23, 2024 | Dexcom G7 Continuous Glucose Monitoring System | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K240902 ↗ |
| Mar 5, 2024 | Stelo Glucose Biosensor System | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K234070 ↗ |
| Feb 26, 2024 | Dexcom G7 Continuous Glucose Monitoring System | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K234133 ↗ |
| Jan 9, 2024 | G5 Mobile Continuous Glucose Monitoring System, G6 Continuo… Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P120005 ↗ |
| May 15, 2023 | Dexcom G7 Continuous Glucose Monitoring (CGM) System | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K231081 ↗ |
| Jan 12, 2023 | DEXCOM G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P120005 ↗ |
| Jan 11, 2023 | Dexcom G6 Continuous Glucose Monitoring (CGM) System | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K223931 ↗ |
| Dec 7, 2022 | Dexcom G7 Continuous Glucose Monitoring System | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K213919 ↗ |
| Jul 29, 2022 | Dexcom G6 Continuous Glucose Monitoring (CGM) System, Dexco… | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K221259 ↗ |
| Jan 20, 2022 | Dexcom G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P120005 ↗ |
| Dec 21, 2021 | G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Aug 17, 2021 | Dexcom G6 Glucose Program Continuous Glucose Monitoring (CG… | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K203089 ↗ |
| Jul 15, 2021 | Dexcom G6 Continuous Glucose Monitoring (CGM) System | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K201328 ↗ |
| Dec 4, 2020 | Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 G… | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K200876 ↗ |
| Sep 3, 2020 | G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P120005 ↗ |
| Jan 29, 2020 | Dexcom G6 Glucose Program Continuous Glucose Monitoring (CG… | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K193642 ↗ |
| Nov 1, 2019 | DEXCOM G5 MOBILE CONTINUOUS GLUCOSE MONITORING SYSTEM Sensor, glucose, invasive, non-adjunctive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P120005 ↗ |
| Oct 25, 2019 | Dexcom G6 Glucose Program Continuous Glucose Monitoring (GC… | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K192787 ↗ |
| Oct 7, 2019 | Dexcom G6 Pro Continuous Glucose Monitoring System | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K191833 ↗ |
| Aug 20, 2019 | Dexcom G4 PLATINUM Continuous Glucose Monitoring System, De… Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Jun 28, 2019 | Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 G… | DXCM Dexcom, Inc. | Device clearance (510(k)) Special | K191450 ↗ |
| Apr 24, 2019 | Dexcom G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Mar 15, 2019 | Dexcom G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P120005 ↗ |
| Feb 14, 2019 | Dexcom G6 Continuous Glucose Monitoring System | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K183206 ↗ |
| Nov 2, 2018 | Dexcom Pro Q Continuous Glucose Monitoring System | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K182405 ↗ |
| Oct 26, 2018 | Dexcom G6 Glucose Program Continuous Glucose Monitoring Sys… | DXCM Dexcom, Inc. | Device clearance (510(k)) Traditional | K182041 ↗ |
| Oct 11, 2018 | G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive, non-adjunctive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Jul 3, 2018 | G5 Mobile transmitter Hardware and Firmware, G5 Mobile Cont… Sensor, glucose, invasive, non-adjunctive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| May 7, 2018 | Dexcom G4 Platinum Continuous Glucose Monitoring System and… Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P120005 ↗ |
| Mar 27, 2018 | Dexcom G6 Continuous Glucose Monitoring System | DXCM Dexcom, Inc. | Device clearance (510(k)) De Novo | DEN170088 ↗ |
| Nov 3, 2017 | Dexcom G4 PLATINUM Continuous Glucose Monitoring System; De… Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P120005 ↗ |
| Sep 21, 2017 | Dexcon G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive, non-adjunctive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Aug 11, 2017 | Dexcom G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Jun 6, 2017 | DEXCOM G5 MOBILE CONTIUOUS GLUCOSE MONITORING SYSTEM Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P120005 ↗ |
| May 22, 2017 | DEXCOM G4 PLATINUM CONTIUOUS GLUCOSE MONITORING SYSTEM Sensor, glucose, invasive, non-adjunctive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P120005 ↗ |
| Mar 8, 2017 | Dexcom G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive, non-adjunctive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P120005 ↗ |
| Dec 20, 2016 | DEXCOM G5 MOBILE CONTINUOUS GLUCOSE MONITORING SYSTEM Sensor, glucose, invasive, non-adjunctive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Panel Track | P120005 ↗ |
| Dec 9, 2016 | DEXCOM G4 PLATINUM CONTIUOUS GLUCOSE MONITORING SYSTEM Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Oct 26, 2016 | DEXCOM G5 MOBILE CONTINUOUS GLUCOSE MONITORING SYSTEM Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Sep 16, 2016 | DEXCOM G5 MOBILE CONTIUOUS GLUCOSE MONITORING SYSTEM Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Aug 2, 2016 | DEXCOM G5 Mobile Continuous Glucose Monitoring System Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
| Jul 8, 2016 | DEXCOM G4 PLATINUM RECEIVER, G4 PLATINUM PEDIATRIC RECEIVER… Sensor, glucose, invasive | DXCM Dexcom, Inc. | Device approval (PMA), supplement Real-Time Process | P120005 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 5:59 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates